Henrik Depenbrock
Eli Lilly (Germany) · 57 works · 1,326 citations · h-index 16
Top works
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin
- Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
- Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
- Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: Comparison with taxol and conventional antineoplastic agents
- In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells
- Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells
- Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.
- Gemcitabine and etoposide in small cell lung cancer: phase I and II trials.
- Effects of cytokines on in vitro colony formation of primary human tumour specimens
- A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).
- Interleukin 1 modulates growth of human renal carcinoma cells in vitro
- Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro
- Effects of the microtubule-disturbing agents docetaxel (taxotere®), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro
- In vitro activity of liposomal N4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells
- Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)
- A phase I study of MTA (multi-targeted antifolate, LY231514) plus cisplatin (CIS) in patients with advanced solid tumours
- Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell linesin vitro
- Characterization and mutual ligand-induced modulation of epidermal growth factor and interferon-α receptors on renal carcinoma cells in vitro
- An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer